Jason carroll_cv

Office Address:
Cancer Research UK/Cambridge Research Institute Place of Birth:
Date of birth:


B.Sc. (Molecular Biology) University of Melbourne (1st Class Honours), Melbourne, Australia Ph.D. (Cancer Research) The Garvan Institute and University of New South Wales, Sydney, Australia
Professional Experience:

Research Assistant, Genomics Disorders Research Centre, St. Vincent’s Institute of Medical Research, Melbourne, Australia Research Associate, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA Instructor of Medicine, Harvard Medical School, Boston, MA Junior Group Leader, Cancer Research UK, Cambridge Research Institute Senior Group Leader, Cancer Research UK, Cambridge Research 2007- Associate faculty, Department of Oncology, University of
Awards and Honors
Dana-Farber/Harvard Cancer Center symposium award 2009 British Association for Cancer Research: Frank Rose Young Funding:
Department of Defense Postdoctoral Fellowship
Supervised PhD students:

Professional activities:

Editorial board: Nucleic Acids Research Associate editor: BMC Cancer Board member: Trends in Endocrinology and Metabolism (Cell Press) Board member: ecancer medical science Member: BACR and EACR

1. Carroll, J.S, Prall, O.W.J, Musgrove, E.A and Sutherland, R.L. A Pure Estrogen
Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces
Accumulation of p130-E2F4 Complexes Characteristic of Quiescence. J Biol Chem.,
2000; 275: 38221-9.
2. Prall, O.W.J, Carroll, J.S and Sutherland, R.L. A low abundance pool of nascent p21
is targeted by estrogen to activate cyclin E-Cdk2. J Biol Chem., 2001, 276: 45433-42
3. Carroll, J.S, Swarbrick, A, Musgrove, E. A and Sutherland, R.L., Mechanisms of
growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells:
Implications for the anti-proliferative effects of antiestrogens. Cancer Res. 2002, 62:

4. Hui, R, Finney, G.L, Carroll, J.S, Lee, C.S, Musgrove, E.A and Sutherland, R.L.
Constitutive cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D
breast cancer cells. Cancer Res. 2002, 62: 6916-23
5. Doisneau-Sixou, S.F, Cestac, P, Chouini, S, Carroll, J.S, Hamilton, A.D, Sebti, S.M,
Poirot, M, Balaguer, P, Faye, J.C, Sutherland, R.L and Favre, G. Contrasting effects of
prenyltransferase estrogen-dependent cell cycle progression and estrogen receptor-
mediated activity in MCF-7 cells. Endocrinology. 2003, 144: 989-98
6. Doisneau-Sixou, S.F, Sergio, C.M, Carroll, J.S, Hui, R, Musgrove, E.A and
Sutherland, R.L. Estrogen and antiestrogen regulation of cell cycle progression in breast
cancer cells. Endocrine Related Cancer. 2003, 10: 179-86

7. Carroll, J.S, Lynch, D.K, Swarbrick, A, Renoir, J-M, Sarcevic, B, Daly, R.J,
Musgrove, E.A and Sutherland, R.L. p27(Kip1) induces quiescence and growth factor
insensitivity in tamoxifen-treated breast cancer cells. Cancer Res. 2003, 63:4322-6
8. Mawson, A, Lai, A, Carroll, J.S, Sergio, C.M, Mitchell, C.J and Sarcevic, B. Estrogen
and insulin/IGF-I cooperatively stimulate cell cycle progression in MCF-7 breast cancer
cells through regulation of c-Myc and cyclin D1. Mol Cell Endo.. 2005, 229:161-73
9. Carroll, J.S, Liu, X.S, Brodsky, A.S, Meyer, C.A, Li, W, Szary, A.J, Eeckhoute, J,
Shao, W, Hestermann, E.V, Geistlinger, T.R, Fox, E.A, Silver, P.A and Brown, M.
Chromosome-wide mapping of Estrogen Receptor binding reveals long-range regulation
requiring the Forkhead protein FoxA1. Cell. 2005, 122:33-43

10. Wang, Q, Carroll, J.S and Brown, M. Novel special and temporal recruitment of
Androgen Receptor and its coactivators leads to chromosomal looping and polymerase
tracking. Mol Cell, 2005, 19:631-42
11. Carroll, D.K, Carroll, J.S, Sofer, A, Cheng, F, Brown, M, Mills, A.A, Brugge, J.S
and Ellisen, L.W. p63 regulates an adhesion program and cell survival in epithelial cells.
Nature Cell Biol., 2006, 8:551-61
12. Carroll, J.S and Brown, M. Estrogen Receptor Target Gene: an Evolving Concept.
Mol Endocrinol., 2006, 20:1707-14
13. Johnson, W. E, Li, W, Meyer, C. A, Gottardo, R, Carroll, J. S, Brown, M and Liu,
X. S. MAT: Model-based analysis of tiling-arrays for ChIP-chip, Proc Natl Acad Sci
, 2006, 103:12457-62
14. Eeckhoute, J, Carroll, J.S, Geistlinger, T.R, Torres-Arzayus, M.I and Brown, M.
Combinatorial transcriptional network required for estrogen regulation of cyclin D1 and
cell cycle progression in breast cancer cells, Genes Dev., 2006, 20:2513-26
15. Carroll, J.S, Meyer, C.A, Song, J, Li, W, Geistlinger, T.R, Eeckhoute, J, Brodsky,
A.S, Keeton, E.K, Fertuck, K.C, Hall, G.F, Wang, Q, Bekiranov, S, Sementchenko, V,
Fox, E.A, Silver, P.A, Gingeras, T.R, Liu, X.S and Brown, M. Genome-wide analysis of
Estrogen Receptor binding sites, Nature Genetics, 2006, 38:1289-97
16. Wang, Q, Li, W, Liu, X.S, Carroll, J.S, Janne, O.A, Chinnaiyan, A.M, Pienta, K.J
and Brown, M. A transcriptional regulatory network governs prostate cancer growth and
survival, Mol Cell, 2007, 27:380-92
17. Schmelzle, T, Mailleux, A.A, Overholtzer, M, Carroll, J.S, Solimini, N.L, Lightcap,
E.S, Veiby, O.P and Brugge, J.S. Functional role and oncogene-regulated expression of
the BH3-only proapoptotic factor Bmf in mammary epithelial anoikis. Proc Natl Acad
, 2007, 104: 3787-92
18. Eeckhoute, J, Keeton, E.K, Lupien, M, Krum, S.A, Carroll, J.S and Brown, M.
Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in
breast cancer. Cancer Res., 2007, 67:6477-83
19. Green, K.A and Carroll, J.S. Oestrogen Receptor mediated transcription and the
influence of co-factors and chromatin state. Nature Reviews Cancer, 2007, 7:713-22

20. Krum, S. A, Miranda-Carboni, G. A, Hauschka, P. V, Carroll, J. S, Lane, T. F,
Freedman, L. P, and Brown, M. Estrogen protects bone by inducing Fas ligand in
Osteoblasts to regulate Osteoclast survival. EMBO J, 2008, 27:535-45
21. Lupien, M, Eeckhoute, J, Meyer, C. A, Wang, Q, Zhang, Y, Li, W, Carroll, J. S, Liu,
X. S and Brown, M. FoxA1 translates epigenetic signatures into enhancer driven lineage-
specific transcription. Cell, 2008, 132:958-70
22. Dietz, S.C and Carroll, J.S. Interrogating the genome to understand ER transcription
in breast cancer cells. Expert Reviews in Molecular Medicine. 2008, 1;10:e10
23. Johnson, D.S, Li, W, Gordon, D.B, Bhattacharjee, A, Curry, B, Ghosh, J, Brizuela, L,
Carroll, J.S, Brown, M et. al. Systematic evaluation of variability in ChIP-chip
experiments using predefined DNA targets. Genome Research, 2008. 18:393-403
24. Li, W, Carroll, J.S, Brown, M and Liu X.S. xMAN: extreme MApping of
OligoNucletoides. BMC Genomics, 2008, 9:S20
25. Holmes, K.A, Song, J.S, Liu, X.S, Brown, M and Carroll, J.S. Nkx3-1 and LEF-1
function as transcriptional inhibitors of Estrogen Receptor activity, Cancer Res., 2008,
68: 7380-85
26. Krum, S.A, Miranda-Carboni, G.A, Lupien, M, Eeckhoute, J, Carroll, J.S and
Brown, M. Unique ER-alpha cistromes control cell type-specific gene regulation. Mol
, 2008, 22: 2393-406.
27. Hurtado, T, Holmes, K.A, Geistlinger, T.R, Hutcheson, I.A, Nicholson, R.I, Brown,
M, Jiang, J, Howat, W, Ali, S and Carroll, J.S. Regulation of ERBB2 by oestrogen
receptor-PAX2 determines response to tamoxifen. Nature, 2008, 456: 663-7.

28. Bhat-Nakshatri, P, Wang, G, Appaiah, H, Luktuke, N, Carroll, J.S, Geistlinger, T.R,
Brown, M, Badve, S, Liu, Y and Nakshatri, H. AKT alters genome-wide Estrogen
Receptor alpha binding and impacts estrogen signalling in breast cancer. Mol Cell Biol.,
2008, 28: 7487-503
29. Xia, X, Lemieux, M, Li, W, Carroll, J. S, Brown, M, Liu, X. S and Kung, A. L.
Integration of chromatin binding and gene expression identifies 2-oxyglutarate-Fe(2+)
dioxygenases as primary HIF-1 targets and reveals determinants of hypoxic responses.
Proc Natl Acad Sci USA, 2009, 106: 4260-5
30. Nucera C, Eeckhoute J, Finn S, Carroll J. S, Ligon A. H, Priolo C, Fadda G, Toner
M, Sheils O, Attard M, Pontecorvi A, Nose V, Loda M and Brown M. FOXA1 Is a
Potential Oncogene in Anaplastic Thyroid Carcinoma. Clin Cancer Res. 2009, 15: 3680-
31. Wang, Q, Li, W, Zhang, Y, Yuan, X, Beroukhim, R, Wang, H, Wu, T, Lupien, M, Carroll, J. S, Manrai, A. K, Janne, O. A, Balk, S. B, Mehra, R, Chinnaiyan, A. M,
Rubin, M. A, True, L, Fiorentino, M, Fiore, C, Loda, M, Kantoff, P. W, Liu, X. S and
Brown, M. Reprogramming of Androgen Receptor function in androgen-independent
prostate cancer, Cell, 2009, 138: 245-56

32. Bhat-Nakshatri, P, Wang, G, Collins, N, Thomson, M, Geistlinger, T. R, Carroll, J.
, Brown, M, Hammond, S, Srour, E, Liu, Y and Nakshatri, H. Estradiol-Regulated
MicroRNAs Control Estradiol Response in Breast Cancer Cells, Nucleic Acids Res.,
2009, 37: 4850-4861

33. Caldon, C. E, Sergio, C. M, Schutte, J, Boersma, M. N, Sutherland, R. L, Carroll, J.
and Musgrove, E. A. Estrogen regulation of cyclin E2 requires cyclin D1, but not c-
Myc. Mol Cell Biol., 2009, 29: 4623-4639
34. Redmond A.M and Carroll, J. S. Defining and targeting transcription factors in
cancer. Genome Biology, 2009, 10: 311.1-311.3
35. Ross-Innes, C. S, Stark, R, Holmes, K. A, Schmidt, D, Spyrou, C, Russell, R, Massie,
C. E, Vowler, S. L, Eldridge, M and Carroll, J. S. Co-operative interaction between
Retinoic Acid Receptor-α and Estrogen Receptor in breast cancer, Genes Dev., 2010, 24:
36. Badve, S, Collins, N. R, Bhat-Nakshatri, P, Turbin, D, Leung, S, Thorat, M, Dunn, S.
E, Geistlinger, T. R, Carroll, J. S, Brown, M, Bose, S, Teitell, M. A and Nakshatri, H.
Subcellular Localization of Activated AKT in ER and PR Expressing Breast Cancers:
Potential Clinical Implications, Am J Path., 2010, 176: 2139-2149
37. Theodorou, V and Carroll, J. S. Estrogen receptor action in three dimensions –
looping the loop. Breast Cancer Res., 2010, 12: 303
38. Schmidt, D, Schwalie, P. C, Ross-Innes, C. S, Hurtado, A, Brown, G. D, Carroll, J.
, Flicek, P and Odom, D. T. A CTCF-independent role for cohesin in tissue-specific
transcription. Genome Research, 2010, 20: 578-588
39. Choy, M-K, Movassagh, M, Siggens, L, Vujic, A, Goddard, M, Sanchez, A, Perkins,
N, Figg, N, Bennett, M, Carroll, J. S and Foo, R. High-throughput sequencing identifies
STAT3 as the DNA-associated factor for p53-NF-kappaB-complex-dependent gene
expression in human heart failure. Genome Medicine, 2010, In Press
40. Zwart, W, Theodorou, V and Carroll, J. S. Estrogen Receptor positive breast cancer:
a multidisciplinary challenge. WIREs, Systems biology and medicine, 2010, In Press
41. Thiruchelvam, P.T.R, Lai, C-F, Hua, H, Thomas, R.S, Hurtado, A, Hudson, W,
Bayly, A.R, Kyle, F.J, Periyasamy, M, Photiou, A, Spivey, A.C, Ortlund, E.A, Whitby,
R.J, Carroll, J.S, Coombes, R.C, Buluwela, L and Ali, S. The liver receptor homolog 1
Nuclear Receptor regulates estrogen receptor expression in breast cancer cells. Breast
Cancer Res Treat
, 2010, In press
42. Lupien, M, Meyer, C.A, Bailey, S.T, Eeckhoute, J, Cook, J, Westerling, T, Zhang, X,
Carroll, J.S, Rhodes, D.R, Liu, X.S and Brown, M. Growth factor stimulation induces a
distinct ER cistrome underlying breast cancer endocrine resistance. Genes Dev., 2010,
24: 2219-27
43. Hurtado, A, Holmes, K.A, Ross-Innes, C.S, Schmidt, D and Carroll, J.S. FoxA1 is
necessary and sufficient for programming Estrogen Receptor function and endocrine
response. Nature Genetics, 2011, 43:27-33
44. Holmes, K.A, Hurtado, A, Brown, G.D, Launchbury, R, Ross-Innes, C.S, Hadfield, J,
Odom, D.T and Carroll, J.S. TLE1 mediates Estrogen Receptor binding and
transcriptional activity in breast cancer cells. Proc Natl Acad Sci USA, 2011, In Press
45. Meyer, K.B, Maia, A-T, O’Reilly, M, Ghoussaini, M, Prathalingham, R, Porter-Gill,
P, Ambs, S, Prokunina-Olsson, L, Carroll, J.S and Ponder B.A.J. A functional variant at
a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. PLOS
, 2011, In Press
46. Robinson, J.L.L, MacArthur, S, Ross-Innes, C.S, Tilley, W.D, Neal, D.E, Mills, I.G
and Carroll, J.S. Androgen Receptor driven transcription in molecular apocrine breast
cancer is mediated by FoxA1. EMBO J, 2011, 30: 3019-27
47. Holland, D.G, Burleigh, A, Git, A, Goldgraben, M.A, Perez-Mancera, P.A, Chin, S.F,
Hurtado, A, Bruna, A, Ali, H.R, Greenwood, W, Dunning, M.J, Samarajiwa, S, Menon,
S, Rueda, O.M, Lynch, A.G, McKinney, S, Ellis, I.O, Eaves, C.J, Carroll, J.S, Curtis, C,
Aparicio, S and Caldas, C. ZNF703 is a common luminal B breast cancer oncogene that
differentially regulates luminal and basal progenitors in human mammary epithelium.
EMBO Mol Med., 2011, 3: 167-80
48. Krijgsman, O, Roepman, P, Zwart, W, Carroll, J.S, Tian, S, de Snoo, F.A, Bender,
R.A, Bernards, R, Glas, A.M. A diagnostic gene profile for molecular subtyping of breast
cancer associated with treatment response. Breast Cancer Res. Treat, 2011, In Press
49. Zwart, W, Theodorou, V, Kok, M, Canisius, S, Linn, S and Carroll, J.S. Estrogen
Receptor co-factor-chromatin specificity in the transcriptional regulation of breast cancer.
EMBO J, 2011, 30: 4764-76
50. Zaret, K.S and Carroll, J.S. Pioneer transcription factors: establishing competence
for gene expression. Genes Dev., 2001, 25: 2227-41
51. Ross-Innes, C.S, Brown, G. D and Carroll, J.S. A co-ordinated interaction between
CTCF and ER in breast cancer cells, BMC Genomics, 2011, 12: 593
52. Ross-Innes, C.S, Stark, R, Teschendorff, A.E, Holmes, K.A, Ali, H.R, Dunning, M.J,
Brown, G.D, Gojis, O, Ellis, I.O, Green, A.R, Ali, S, Chin, S.F, Palmieri, C, Caldas, C
and Carroll, J.S. Differential oestrogen receptor binding is associated with clinical
outcome in breast cancer. Nature, 2012, 481: 389-93
53. Jozwik K. M and Carroll, J.S. Pioneer factors in hormone dependent cancers. Nature
Reviews Cancer
, 2012, In Press
Book Chapters

1. Watts, C.K.W., O.W.J. Prall, J.S. Carroll, N.R.C. Wilcken, E.M. Rogan, E.A.
Musgrove and R. L. Sutherland. 1998. Antiestrogens and the cell cycle. In: Jordan, V.C.
and Furr, B.J., ed(s). p 17-45. Antiestrogens and antiandrogens. Humana Press, Totowa,
New Jersey
2. Carroll, J.S., O.W.J. Prall, C.M. Sergio, E.M. Rogan, C.K.W. Watts, E.A. Musgrove
and R.L. Sutherland. 2001. Estrogen/estrogen antagonist regulation of the cell cycle in
breast cancer cells. In: Burnstein, K.L ed. P 57-71. Steroid hormones and cell cycle
regulation. Kluwer Academic Publishers, Boston, Massachusetts

Invited Seminars

1. International Conference on Endocrinology (ICE), Sydney, Australia, 2000
2. Endocrine Society of Australia, Gold Coast, Australia, 2001
3. Harvard/DFCI Annual Breast Cancer Symposium, Boston, USA, 2005
4. Novartis Institute of Biomedical Research, Cambridge, USA, 2005
5. Biomedicum Institute, University of Helsinki, Finland, 2005
6. Affymetrix Users Meeting, Singapore, 2006
7. CCA Symposium in Oncogenomics and Proteomics, Amsterdam, Netherlands, 2006
8. Affymetrix Users meeting, Dublin, Ireland, 2007
9. Society for Endocrinology, BES, Birmingham, UK, 2007
10. Imperial College London (Hammersmith), London, UK, 2007
11. Affymetrix Meeting, University College Dublin, Ireland, 2007
12. Victorian Breast Cancer Research Consortium, Australia, 2007
13. Affymetrix ChIP-chip symposium, Boston, USA, 2007
14. NCRI, ChIP-chip meeting, Birmingham, UK, 2007
15. Garvan Institute of Medical Research, Sydney, Australia, 2007
16. CSC/IC, Microarray Centre, Hammersmith, London, UK, 2007
17. Genome Institute of Singapore, Singapore, 2007
18. Breakthrough Institute, London, UK, 2008
19. University of Dundee, Dundee, UK, 2008
20. CRESCENDO meeting, Munich, Germany, 2008 21. Marie-Curie GARD meeting, Madrid, Spain, 2008 22. The Novum lecture, Karolinska Institute, Stockholm, Sweden, 2008 23. ResisTH network, Tolouse, France, 2008 24. Newcastle University, Newcastle, UK, 2009 25. EACR Meeting, Cambridge, UK, 2009 26. Nuclear Receptor meeting, Spetses Island, Greece, 2009 27. NCRI Annual Cancer meeting, Birmingham, UK, 2009 28. Keystone meeting, Killarney, Ireland, UK. 2009 29. University of Edinburgh, UK, 2009 30. NCI/NIH meeting, Bethesda, USA, 2009 31. Imperial College, London, 2009 32. University of Turin, Italy, 2010 33. Paterson Institute, Manchester, UK, 2010 34. University of Leeds, UK, 2010 35. Gordon Mammary Gland conference, Tuscany, Italy, 2010 36. VUMC, Amsterdam, The Netherlands, 2010 37. Keystone meeting, Keystone, Colorado, USA, 2010 38. University of Nottingham, UK, 2010 39. University of Manchester, UK, 2010 40. Peter MacCallum cancer Institute, Melbourne, Australia, 2010 41. Walter Eliza Hall Institute (WEHI), Melbourne, Australia, 2010 42. Genome Institute of Singapore, Singapore, 2010 43. Plenary talk, British breast cancer conference, Nottingham, UK, 2010 44. Plenary talk, Young prostate researchers symposium, UK, 2010 45. International Aromatase meeting, Edinburgh, UK, 2010 46. Biomedicum Institute, Helsinki, Finland, 2010 47. Karolinska Institute, Stockholm, Sweden, 2010 48. NKI, Amsterdam, The Netherlands, 2011 49. Breast SSG meeting, Cambridge, 2011 50. Irish Association for cancer research meeting, Cork, Ireland, 2011 51. Gordon Hormone action conference, Rhode Island, USA, 2011 53. EMBO meeting, Barcelona, Spain, 2011 54. EMBO YIP meeting, Heidelberg, Germany, 2011 55. Bone Biology forum, Mt Fuji, Japan, 2011 56. University of Tokyo, Japan, 2011 57. Teijin, Japan 2011 58. Nuclear Receptor research network, Amsterdam, Netherlands, 2011 59. Newcastle University, UK, 2011 60. University of Oxford, UK, 2011 61. EMBO chromatin YIP, Heidelberg, Germany, 2011 62. Centre for molecular medicine, Oslo, Norway, 2012 63. Josephine Nefkins Institute, Rotterdam, The Netherlands, 2012 64. Society for Endocrinology, BES, Harrogate, UK, 2012 65. University of Toronto, Canada, 2012 66. Sanger Institute, Cambridge, UK, 2012 67. Queen’s University, Belfast, N. Ireland, 2012 68. IGBMC, Strasbourg, France, 2012 69. Université Libre de Bruxelles, Brussels, 2012 70. Metabolism and Endocrinology summer school, Denmark, 2012 71. NCRI, Liverpool, UK, 2012 72. Genes and Cancer, Warwick, UK, 2012 73. Plenary lecture, San Antonio breast cancer meeting, TX, USA, 2012

Source: http://www.carroll-lab.org.uk/FreshFiles/CVs/Jason%20Carroll_CV_2012_May.pdf

030814 methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis

The new england journal of medicineMethotrexate versus Cyclosporine in Moderate-Vera M.R. Heydendael, M.D., Phyllis I. Spuls, M.D., Ph.D., Brent C. Opmeer, Ph.D., Corianne A.J.M. de Borgie, Ph.D., Johannes B. Reitsma, M.D., Ph.D., Wouter F.M. Goldschmidt, M.D., Patrick M.M. Bossuyt, Ph.D.,Jan D. Bos, M.D., Ph.D., and Menno A. de Rie, M.D., Ph.D. b a c k g r o u n d Methotrexate and cy

Emergency contraception key facts and instructions for use

VT Form C: Key Facts and Instructions for Use Note: A copy of this form must be given to the client. This fact sheet may not be altered. Emergency Contraception (EC) is a safe and ECP’s won’t cause an abortion. effective way to prevent pregnancy after sex. • Emergency Contraception pills are not the Consider using Emergency Contraception if you didn’t use a co

Copyright © 2010 Medicament Inoculation Pdf